Companies in #Hypoxia Biology
Found 1 company operating in this sector.
Akebia Therapeutics, Inc. is a fully integrated commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia markets Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved by the U.S. FDA in March 2024 for the treatment of anemia due to chronic kidney disease in adult dialysis patients, and Auryxia® (ferric citrate) for hyperphosphatemia and iron deficiency anemia. In its Q3 2026 Form 10-Q filing on November 5, 2026, Akebia disclosed an implemented 7% workforce reduction (~14 roles out of 194 staff) to streamline operational expenses and align capital with core commercial priorities, recording $1.3 million in quarterly restructuring charges while holding $159.3 million in cash and cash equivalents.